Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medigen Biotechnology's enterprise value is NT$7,047 Mil.
Medigen Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-79 Mil. Therefore, Medigen Biotechnology's EV-to-EBITDA for today is -89.50.
The historical rank and industry rank for Medigen Biotechnology's EV-to-EBITDA or its related term are showing as below:
ROCO:3176'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -310.62 Med: -13.67 Max: 70.41
Current: -89.5
During the past 13 years, the highest EV-to-EBITDA of Medigen Biotechnology was 70.41. The lowest was -310.62. And the median was -13.67.
ROCO:3176's EV-to-EBITDA is ranked worse than 100% of 399
companies
in the Biotechnology industry
Industry Median: 13.7
vs ROCO:3176: -89.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medigen Biotechnology's PE Ratio (TTM) for today is calculated as:
Medigen Biotechnology's share price for today is NT$34.75.
Medigen Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.820.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Medigen Biotechnology EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Medigen Biotechnology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3176 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Medigen Biotechnology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's EV-to-EBITDA falls into.
Medigen Biotechnology's current Enterprise Value is NT$7,047 Mil.
Medigen Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology (ROCO:3176) has a EV-to-EBITDA of -89.50 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medigen Biotechnology. According to the industry distribution chart, Medigen Biotechnology ranks #999999 out of 399 companies in the Biotechnology industry.
Is Medigen Biotechnology's EV-to-EBITDA too high?
Medigen Biotechnology's current EV-to-EBITDA is -89.50. Based on the distribution chart, Medigen Biotechnology ranks #999999 out of 399 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Biotechnology ranks #999999 out of 399 companies for EV-to-EBITDA. This places Medigen Biotechnology in the lower half of its industry. The industry median EV-to-EBITDA is 13.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medigen Biotechnology. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Biotechnology's current EV-to-EBITDA is -89.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Fairly Valued. The stock's GF Value™ is NT$32.87, compared to a current price of NT$34.75 — trading 5.7% above its estimated fair value. The current EV-to-EBITDA is -89.50. Medigen Biotechnology's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current EV-to-EBITDA is -89.50 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be overvalued.
The current stock price of NT$34.75 is trading 5.7% above its estimated GF Value™ of NT$32.87.
GuruFocus considers Medigen Biotechnology to be Fairly Valued.
Key valuation signals for ROCO:3176:
EV-to-EBITDA: -89.50
GF Value™: NT$32.87 vs. price of NT$34.75 (5.7% above fair value)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score
Get the complete analysis for ROCO:3176
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
